Abstract
The metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors, including central obesity, hyperglycemia, dyslipidemia and hypertension, which are highly associated with increased morbidity and mortality of cardiovascular diseases (CVD). The association between these metabolic disorders and the development of CVD is believed to be multifactorial, where insulin resistance, oxidative stress, low-grade inflammation and vascular maladaptation act as the major contributors. Therefore, multipronged therapeutic strategies should be taken for the management of patients with MetS. Lifestyle changes including weight control, healthy heart diet and regular exercises have been proposed as first line treatment to decrease CVD risks in MetS individuals. In addition, improving insulin resistance and glucose metabolism, controlling blood pressure as well as modulating dyslipidemia can also delay or reverse the progression of CVD in MetS. This review will first address the complicated interactions between MetS and CVD¸ followed by discussion about the optimal strategy in the prevention and treatment of CVD in MetS patients and the updated results from newly released clinical trials.
Keywords: Metabolic syndrome, cardiovascular disease, insulin resistance, obesity, diabetes, dyslipidemia.
Current Pharmaceutical Design
Title:Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome
Volume: 19 Issue: 27
Author(s): Yabin Wang, Qiujun Yu, Yundai Chen and Feng Cao
Affiliation:
Keywords: Metabolic syndrome, cardiovascular disease, insulin resistance, obesity, diabetes, dyslipidemia.
Abstract: The metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors, including central obesity, hyperglycemia, dyslipidemia and hypertension, which are highly associated with increased morbidity and mortality of cardiovascular diseases (CVD). The association between these metabolic disorders and the development of CVD is believed to be multifactorial, where insulin resistance, oxidative stress, low-grade inflammation and vascular maladaptation act as the major contributors. Therefore, multipronged therapeutic strategies should be taken for the management of patients with MetS. Lifestyle changes including weight control, healthy heart diet and regular exercises have been proposed as first line treatment to decrease CVD risks in MetS individuals. In addition, improving insulin resistance and glucose metabolism, controlling blood pressure as well as modulating dyslipidemia can also delay or reverse the progression of CVD in MetS. This review will first address the complicated interactions between MetS and CVD¸ followed by discussion about the optimal strategy in the prevention and treatment of CVD in MetS patients and the updated results from newly released clinical trials.
Export Options
About this article
Cite this article as:
Wang Yabin, Yu Qiujun, Chen Yundai and Cao Feng, Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome, Current Pharmaceutical Design 2013; 19 (27) . https://dx.doi.org/10.2174/1381612811319270002
DOI https://dx.doi.org/10.2174/1381612811319270002 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Exploring Modifications in Fetal Telomere Programming in Mothers Exposed to Multiple Risk Factors
Current Women`s Health Reviews The Osteopontin Tissue Level as a Breast Cancer Biomarker in Females After Mastectomy Measured by the Capillary Gel Electrophoresis Technique
Combinatorial Chemistry & High Throughput Screening Nattokinase: An Updated Critical Review on Challenges and Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry The Roles of Abnormal Renal Sodium Handling in Hypertension Associated with Metabolic Syndrome
Current Hypertension Reviews Neural Mechanisms of Exercise: Effects on Gut Miccrobiota and Depression
CNS & Neurological Disorders - Drug Targets Gene Patents Related to Common Diseases of the Eye
Recent Patents on DNA & Gene Sequences Concerning Arterial Hypertension, Homocysteine and Paraoxonase-1
Current Hypertension Reviews Sleep Disordered Breathing: Alternatives to CPAP Therapy
Current Respiratory Medicine Reviews Patent Review
Combinatorial Chemistry & High Throughput Screening Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design Nanocrystalline ZnO: A Competent and Reusable Catalyst for the Preparation of Pharmacology Relevant Heterocycles in the Aqueous Medium
Current Green Chemistry Calcium and Vitamin D Supplementation. Myths and Realities with Regard to Cardiovascular Risk
Current Vascular Pharmacology Regulation of Endothelial Nitric Oxide Synthase in Pathophysiological Conditions
Cardiovascular & Hematological Disorders-Drug Targets Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Current Topics in Medicinal Chemistry Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a Biomarker for Acute Kidney Injury
Recent Patents on Biomarkers MicroRNAs: A Critical Regulator and a Promising Therapeutic and Diagnostic Molecule for Diabetic Cardiomyopathy
Current Gene Therapy Sex Differences in Oxidative Stress Biomarkers
Current Drug Targets Nearly Half of Uncontrolled Hypertensive Patients could be Controlled by High-dose Titration of Amlodipine in the Clinical Setting: The ACHIEVE Study
Current Hypertension Reviews Phytochemical Genistein in the Regulation of Vascular Function: New Insights
Current Medicinal Chemistry